Adapsyn Bioscience receives funding to discover novel therapeutics for TB

HAMILTON, ON, Oct. 18, 2022 - Adapsyn Bioscience Inc., a chemical bioinformatics company that discovers novel drug-like small molecules, today announced that it has received funding from the Bill & Melinda Gates Foundation to find novel therapeutics that target tuberculosis (TB). Globally, TB remains a leading cause of death from infectious disease, and factors such as a growing resistance to current drug therapies have created an urgent need for new treatments to combat its spread. Adapsyn's discovery platform integrates artificial intelligence and machine learning to identify and isolate novel drug-like metabolites from microbes for downstream evaluation and development. Adapsyn will utilize the full capabilities of its platform to identify novel small molecules that inhibit established and emerging targets in Mycobacterium tuberculosis, the causative agent of the disease, which will help fuel the development of next-generation anti-TB drugs. The company will collaborate with leaders in TB research on target selection, bioactivity testing, and target confirmation.